20-37944140-A-G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The ENST00000373461.9(VSTM2L):āc.502A>Gā(p.Asn168Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00031 in 1,607,576 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 10/16 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Consequence
ENST00000373461.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
VSTM2L | NM_080607.3 | c.502A>G | p.Asn168Asp | missense_variant | 4/4 | ENST00000373461.9 | NP_542174.1 | |
VSTM2L | XM_011528530.2 | c.451A>G | p.Asn151Asp | missense_variant | 3/3 | XP_011526832.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
VSTM2L | ENST00000373461.9 | c.502A>G | p.Asn168Asp | missense_variant | 4/4 | 1 | NM_080607.3 | ENSP00000362560.4 | ||
VSTM2L | ENST00000373459.4 | c.281A>G | p.Glu94Gly | missense_variant | 2/2 | 3 | ENSP00000362558.4 | |||
VSTM2L | ENST00000448944.1 | c.*4A>G | downstream_gene_variant | 3 | ENSP00000406537.1 |
Frequencies
GnomAD3 genomes AF: 0.000270 AC: 41AN: 151878Hom.: 0 Cov.: 29
GnomAD3 exomes AF: 0.000336 AC: 79AN: 235218Hom.: 0 AF XY: 0.000421 AC XY: 54AN XY: 128400
GnomAD4 exome AF: 0.000314 AC: 457AN: 1455698Hom.: 0 Cov.: 45 AF XY: 0.000304 AC XY: 220AN XY: 723548
GnomAD4 genome AF: 0.000270 AC: 41AN: 151878Hom.: 0 Cov.: 29 AF XY: 0.000229 AC XY: 17AN XY: 74168
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 07, 2022 | The c.502A>G (p.N168D) alteration is located in exon 4 (coding exon 4) of the VSTM2L gene. This alteration results from a A to G substitution at nucleotide position 502, causing the asparagine (N) at amino acid position 168 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at